Trial Profile
A Phase 2a, Open-Label Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 16 Feb 2024
Price :
$35
*
At a glance
- Drugs Elebsiran (Primary) ; Nivolumab (Primary) ; Selgantolimod (Primary) ; Tenofovir alafenamide (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors Gilead Sciences
- 21 Dec 2022 Planned End Date changed from 1 Apr 2024 to 1 Jan 2024.
- 21 Dec 2022 Planned primary completion date changed from 1 Oct 2023 to 1 Jan 2024.
- 21 Dec 2022 Status changed from recruiting to active, no longer recruiting.